safety and tolerability

Showing 1 - 18 of 18

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Safety and Tolerability Trial in Shanghai (JMKX003142 will be administered orally, Placebo in Cohorts 1 to 7, Placebo in 3

Recruiting
  • Safety and Tolerability
  • JMKX003142 will be administered orally
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Oct 13, 2023

Safety and Tolerability Trial in Neuss (ZP7570, Placebo)

Not yet recruiting
  • Safety and Tolerability
  • Neuss, North Rhine-Westphalia, Germany
    Profil Institut für Stoffwechselforschung GmbH
Aug 18, 2023

Healthy, Safety and Tolerability Trial in Cypress (DF-003, Placebo)

Recruiting
  • Healthy
  • Safety and Tolerability
  • Cypress, California
    Altasciences Clinical Los Angeles, Inc
Aug 9, 2023

Safety and Tolerability Trial in Shanghai (JMKX003002 will be administered orally, Placebo in Cohorts 1 to 5, Placebo in 2

Recruiting
  • Safety and Tolerability
  • JMKX003002 will be administered orally
  • +2 more
  • Shanghai, Shanghai, China
    Huashan Hospital Fudan University
Jun 15, 2023

Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)

Active, not recruiting
  • Advanced Solid Malignancy
  • +13 more
  • Los Angeles, California
  • +33 more
Dec 22, 2022

Healthy Adult Subjects, Pharmacokinetics, Safety and Tolerability Trial in Baltimore (Low dose KT07, High dose KT07, Low dose

Completed
  • Healthy Adult Subjects
  • +2 more
  • Low dose KT07
  • +3 more
  • Baltimore, Maryland
    Pharmaron
Oct 13, 2022

Safety and Tolerability Trial in Baltimore (YJ001 for Spray Use, Placebo of YJ001 for Spray Use)

Not yet recruiting
  • Safety and Tolerability
  • YJ001 for Spray Use
  • Placebo of YJ001 for Spray Use
  • Baltimore, Maryland
    Pharmaron CPC, Inc.
Jul 5, 2022

Safety and Tolerability Trial in Glendale (Experimental drug: ESK-001, Placebo)

Recruiting
  • Safety and Tolerability
  • Experimental drug: ESK-001
  • Placebo
  • Glendale, California
    Alumis Central site
Jun 20, 2022

Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)

Completed
  • Hepatitis
  • Safety and Tolerability
  • HEPLISAV-B
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 13, 2022

Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI

Active, not recruiting
  • Safety and Tolerability
  • +3 more
  • Zoster Vaccine Recombinant, Adjuvanted
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 10, 2022

Safety and Tolerability Trial in Leeds (GB1211, Placebo)

Completed
  • Safety and Tolerability
  • Leeds, United Kingdom
    (For Parts A and B) Covance Clinical Research Unit Ltd
Feb 25, 2021

Safety and Tolerability Trial in Turku (GT-002, Placebo oral capsule)

Completed
  • Safety and Tolerability
  • Turku, Finland
    CRST Oy, Clinical Research Services Turku
Feb 4, 2020

Safety and Tolerability Trial in Cypress (inhaled human insulin, Insulin Lispro (Humalog U-100))

Terminated
  • Safety and Tolerability
  • inhaled human insulin
  • Insulin Lispro (Humalog U-100)
  • Cypress, California
    WCCT
Sep 11, 2019

Safety and Tolerability Trial in Miami (Sevuparin)

Completed
  • Safety and Tolerability
  • Miami, Florida
    Clinical Pharmacology of Miami (CPMI)
Jul 15, 2019

Safety and Tolerability Trial in Leeds (DP13, )

Completed
  • Safety and Tolerability
  • Leeds, United Kingdom
    Covance Clinical Research Unit Ltd
Apr 13, 2018

Safety and Tolerability Trial in Phoenix (Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days)

Completed
  • Safety and Tolerability
  • Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
  • Phoenix, Arizona
    Pulmonary Associates, PA
Feb 17, 2017

Safety and Tolerability Trial in London (ACT-128800, Placebo)

Completed
  • Safety and Tolerability
  • London, United Kingdom
    Quintiles Drug Research Unit at Guy's Hospital
Jan 6, 2014

Safety and Tolerability Trial in Austin (K-312, Placebo)

Completed
  • Safety and Tolerability
  • Austin, Texas
    (unnamed)
Dec 30, 2013